These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32096041)

  • 1. Tau PET Imaging.
    Higuchi M
    Adv Exp Med Biol; 2019; 1184():217-230. PubMed ID: 32096041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in Tau PET Imaging.
    Zimmer ER; Leuzy A; Gauthier S; Rosa-Neto P
    Can J Neurol Sci; 2014 Sep; 41(5):547-53. PubMed ID: 25424608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the development of tau PET radiotracers and their clinical applications.
    Okamura N; Harada R; Furukawa K; Furumoto S; Tago T; Yanai K; Arai H; Kudo Y
    Ageing Res Rev; 2016 Sep; 30():107-13. PubMed ID: 26802556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Tau and Its Ligands in PET Imaging.
    Harada R; Okamura N; Furumoto S; Tago T; Yanai K; Arai H; Kudo Y
    Biomolecules; 2016 Jan; 6(1):7. PubMed ID: 26751494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies.
    Tagai K; Ono M; Kubota M; Kitamura S; Takahata K; Seki C; Takado Y; Shinotoh H; Sano Y; Yamamoto Y; Matsuoka K; Takuwa H; Shimojo M; Takahashi M; Kawamura K; Kikuchi T; Okada M; Akiyama H; Suzuki H; Onaya M; Takeda T; Arai K; Arai N; Araki N; Saito Y; Trojanowski JQ; Lee VMY; Mishra SK; Yamaguchi Y; Kimura Y; Ichise M; Tomita Y; Zhang MR; Suhara T; Shigeta M; Sahara N; Higuchi M; Shimada H
    Neuron; 2021 Jan; 109(1):42-58.e8. PubMed ID: 33125873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tau Positron Emission Tomography].
    Higuchi M
    Brain Nerve; 2017 Jul; 69(7):819-823. PubMed ID: 28739996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tau Positron Emission Tomography: Applications in Diagnosis and Prognosis of Various Diseases].
    Takahata K; Kubota M; Kurose S; Higuchi M
    Brain Nerve; 2024 Sep; 76(9):1035-1044. PubMed ID: 39251223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy.
    Murugan NA; Nordberg A; Ågren H
    ACS Chem Neurosci; 2021 Jul; 12(13):2437-2447. PubMed ID: 34152739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [
    Lagarde J; Olivieri P; Caillé F; Gervais P; Baron JC; Bottlaender M; Sarazin M
    J Neurol; 2019 Dec; 266(12):3087-3097. PubMed ID: 31535269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau imaging with PET: an overview of challenges, current progress, and future applications.
    Robertson JS; Rowe CC; Villemagne VL
    Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):405-413. PubMed ID: 28750496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau PET imaging in Alzheimer's disease.
    Okamura N; Harada R; Furumoto S; Arai H; Yanai K; Kudo Y
    Curr Neurol Neurosci Rep; 2014 Nov; 14(11):500. PubMed ID: 25239654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau PET imaging: present and future directions.
    Saint-Aubert L; Lemoine L; Chiotis K; Leuzy A; Rodriguez-Vieitez E; Nordberg A
    Mol Neurodegener; 2017 Feb; 12(1):19. PubMed ID: 28219440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau PET imaging in neurodegenerative tauopathies-still a challenge.
    Leuzy A; Chiotis K; Lemoine L; Gillberg PG; Almkvist O; Rodriguez-Vieitez E; Nordberg A
    Mol Psychiatry; 2019 Aug; 24(8):1112-1134. PubMed ID: 30635637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351.
    Oh M; Oh SJ; Lee SJ; Oh JS; Roh JH; Chung SJ; Lee JH; Lee CS; Kim JS
    Clin Nucl Med; 2020 Nov; 45(11):841-847. PubMed ID: 32910050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-based design of [
    Lindberg A; Murrell E; Tong J; Mason NS; Sohn D; Sandell J; Ström P; Stehouwer JS; Lopresti BJ; Viklund J; Svensson S; Mathis CA; Vasdev N
    Nat Commun; 2024 Jun; 15(1):5109. PubMed ID: 38877019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and preclinical characterization of [
    Kroth H; Oden F; Molette J; Schieferstein H; Capotosti F; Mueller A; Berndt M; Schmitt-Willich H; Darmency V; Gabellieri E; Boudou C; Juergens T; Varisco Y; Vokali E; Hickman DT; Tamagnan G; Pfeifer A; Dinkelborg L; Muhs A; Stephens A
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2178-2189. PubMed ID: 31264169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders.
    Maeda J; Zhang MR; Okauchi T; Ji B; Ono M; Hattori S; Kumata K; Iwata N; Saido TC; Trojanowski JQ; Lee VM; Staufenbiel M; Tomiyama T; Mori H; Fukumura T; Suhara T; Higuchi M
    J Neurosci; 2011 Mar; 31(12):4720-30. PubMed ID: 21430171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau PET Imaging in Neurodegenerative Disorders.
    Groot C; Villeneuve S; Smith R; Hansson O; Ossenkoppele R
    J Nucl Med; 2022 Jun; 63(Suppl 1):20S-26S. PubMed ID: 35649647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for tau pathology.
    Schöll M; Maass A; Mattsson N; Ashton NJ; Blennow K; Zetterberg H; Jagust W
    Mol Cell Neurosci; 2019 Jun; 97():18-33. PubMed ID: 30529601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease.
    Tago T; Furumoto S; Okamura N; Harada R; Adachi H; Ishikawa Y; Yanai K; Iwata R; Kudo Y
    J Nucl Med; 2016 Apr; 57(4):608-14. PubMed ID: 26697966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.